Durr FE - Search Results

1

Molecular and biochemical pharmacology of mitoxantrone.

Durr FE, Wallace RE, Citarella RV. Durr FE, et al. Cancer Treat Rev. 1983 Dec;10 Suppl B:3-11. doi: 10.1016/0305-7372(83)90016-6. Cancer Treat Rev. 1983. PMID: 6362876 Review.

2

Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro.

Wallace RE, Lindh D, Durr FE. Wallace RE, et al. Among authors: durr fe. Cancer Invest. 1987;5(5):417-28. doi: 10.3109/07357908709032899. Cancer Invest. 1987. PMID: 3427507

3

Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.

Wallace RE, Murdock KC, Angier RB, Durr FE. Wallace RE, et al. Among authors: durr fe. Cancer Res. 1979 May;39(5):1570-4. Cancer Res. 1979. PMID: 427798

4

Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.

Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M. Citarella RV, et al. Among authors: durr fe. Cancer Res. 1982 Feb;42(2):440-4. Cancer Res. 1982. PMID: 7055799

5

Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).

Wang BS, Ruszala-Mallon V, Wallace RE, Citarella RV, Lin YI, Durr FE. Wang BS, et al. Among authors: durr fe. Cancer Immunol Immunother. 1986;22(1):8-14. doi: 10.1007/BF00205710. Cancer Immunol Immunother. 1986. PMID: 2939949 Free PMC article.

6

Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones.

Murdock KC, Child RG, Fabio PF, Angier RB, Wallace RE, Durr FE, Citarella RV. Murdock KC, et al. Among authors: durr fe. J Med Chem. 1979 Sep;22(9):1024-30. doi: 10.1021/jm00195a002. J Med Chem. 1979. PMID: 490545

7

Induction of alloreactive immunosuppression by 1,4-bis [( 2-aminoethyl)amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (CL 232,468).

Wang BS, Lumanglas AL, Ruszala-Mallon VM, Wallace RE, Durr FE. Wang BS, et al. Among authors: durr fe. Int J Immunopharmacol. 1984;6(5):475-82. doi: 10.1016/0192-0561(84)90086-9. Int J Immunopharmacol. 1984. PMID: 6334042

8

Tissue deposition of bisantrene in B16 melanoma tumor-bearing mice.

Nicolau G, Wu WH, McWilliams W, Citarella RV, Durr FE. Nicolau G, et al. Among authors: durr fe. Cancer Invest. 1986;4(1):25-8. doi: 10.3109/07357908609039824. Cancer Invest. 1986. PMID: 3955418

9

Antitumor agents. 2. Bisguanylhydrazones of anthracene-9,10-dicarboxaldehydes.

Murdock KC, Child RG, Lin Y, Warren JD, Fabio PF, Lee VJ, Izzo PT, Lang SA Jr, Angier RB, Citarella RV, Wallace RE, Durr FE. Murdock KC, et al. Among authors: durr fe. J Med Chem. 1982 May;25(5):505-18. doi: 10.1021/jm00347a006. J Med Chem. 1982. PMID: 6806475

10

Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Hinman LM, et al. Among authors: durr fe. Cancer Res. 1993 Jul 15;53(14):3336-42. Cancer Res. 1993. PMID: 8324745

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters